Then $245 million. In August, United Therapeutics sold a priority review voucher to Abbvie for $350 million. The others remain unused and if they have been sold, it hasn’t yet been disclosed.

Are Priority Review Vouchers The Answer To Incentivize Drug Development? Not So Fast. Pranav Aurora Morgan Romine Gregory Daniel June 15, 2016 10.1377/forefront.20160615.055372 Add to favorites ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A Priority Review Voucher Program To Fuel Generic Drug Development Ted Cho Patrick Dumas Brian J. Miller July 6, 2023 10.1377/forefront.20230705.334685 Sections ...

Based on positive Phase II TRANSCEND FL data showing a 95.5% overall response rate, the FDA has accepted Bristol Myers Squibb’s sBLA for Breyanzi in relapsed or refractory MZL with a PDUFA date set ...

References FDA grants Priority Review to SpringWorks Therapeutics’ New Drug Application for mirdametinib for the treatment of adults and children with NF1-PN. News release. SpringWorks.

Priority Home Warranty has excellent reviews on Google of 4.8 stars and Trustpilot of 4.4 stars. The company has also been mentioned on NBC, CBS, USA Today and other well-known media sources.

Kyowa Hakko Kirin and Ultragenyx Pharmaceutical recently sold a priority review voucher for $80.6 million to an undisclosed buyer. That’s half the average value that nine previous vouchers sold for.

By granting priority review, the FDA commits to making a decision within six months. Gleevec was approved more than a year ago for treating a type of leukemia when the disease is in its later stages.